Sandy W. Wong, MD
Patients in late relapse comprise one of the largest unmet needs in multiple myeloma, said Sandy Wong, MD, but added that monoclonal antibodies and antibody-drug conjugates (ADCs) are the biggest potentially practice-changing agents in this setting.
State of the Science Summit™ on Hematologic Malignancies, Wong discussed emerging agents being explored for the treatment of patients with multiple myeloma in late relapse.
OncLive: What are some of the agents being explored for patients in late relapse?
There are a lot of clinical trials being studied in that population right now. It is also the population of greatest unmet medical need. The first trial I went over was a daratumumab-based trial. Daratumumab has been used in multiple different combinations in both the newly diagnosed as well as in the relapsed setting.
... to read the full story